Project Grant R21CA296705
Award Date 9/1/25
Completion Date 8/31/27
Dollars Obligated $483K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Pennsylvania, USA
Similar Awards
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding to the Dana-Farber Cancer Institute (DFCI) to investigate targeting the CDK4/6 pathway as a potential therapeutic strategy for translocation renal cell carcinoma (TRCC), an aggressive form of kidney cancer. The $267,298 award, effective from February 1, 2025 to January 31, 2027, will support in vitro and in vivo studies to test the sensitivity of TRCC cells to CDK4/6 inhibition,...
- This $396,061 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research to assess the efficacy of a novel class of hypoxia-inducible factor (HIF) inhibitors as a potential treatment for renal cell carcinoma (RCC). The principal investigator has developed boron-based HIF inhibitors derived from the natural compound honokiol, which have demonstrated promising anti-angiogenic properties in vitro. This 2-year project aims to (1) determine...
- This federal Project Grant award of $400,000 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports the advancement of next-generation CAR-T cell therapies for renal cell carcinoma (RCC). The award recipient, Cellinfinity Bio Inc., is developing novel CAR-T cell modifications, including a PRDM1 exon 3 knockout and a CTLA-4 cytoplasmic tail fusion, to enhance CAR-T cell efficacy against RCC tumors. The project aims to evaluate the combination of these...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $415,000.00 to Mayo Clinic to conduct research aimed at enhancing the effectiveness of immune checkpoint blockade (ICB) immunotherapy for renal cell carcinoma (RCC). The project seeks to demonstrate that disrupting the ubiquitination or phosphorylation of the RIPK1 protein in RCC tumor cells can increase their susceptibility to killing by T cells in a TNF-dependent manner, thereby...
- This $521,579 Project Grant award, provided by the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), supports research to identify critical regulators controlling clear cell renal cell carcinoma (CCRCC) lung metastasis. The University of Texas Southwestern Medical Center, the awardee, will conduct a genome-wide CRISPR screen to characterize the role of the hepatic leukemia factor (HLF) in CCRCC lung metastasis and examine the underlying molecular...
- The federal Project Grant award for $172,193 was provided by the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398) to the Dana-Farber Cancer Institute, Inc. (DFCI) located in Massachusetts. The goal of this 5-year project is to characterize subtype-specific gene regulatory elements in translocation renal cell carcinoma (TRCC), a rare and aggressive form of kidney cancer, by identifying differentially active transcription factors, determining their metabolic...
- The federal Project Grant award for "TARGETING P2X7 RECEPTOR IN RENAL CELL CARCINOMA", totaling $1,269,000.00, was awarded to The Institute For Cancer Research, a non-profit subsidiary of Temple University, by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The award supports biomedical research focused on developing new treatments for kidney cancer, a key health concern for military service members and veterans. The Institute For...
- This $189,163 federal Project Grant award from the National Cancer Institute under the Cancer Cause and Prevention Research program (CFDA 93.393) aims to investigate the impact of dietary patterns and physical activity on survival outcomes for patients with renal cell carcinoma (RCC). The research team at Brigham & Women's Hospital, with the University of California, San Francisco as a sub-grantee, will leverage data from three large, prospective cohorts to comprehensively evaluate pre-...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding of $186,000.00 to The Institute For Cancer Research (ICR) to conduct pilot studies on a new tumor-targeted AURKA (Aurora-A Kinase) inhibitor called NN-01-195. The goal is to investigate the feasibility and potential of this novel chimeric compound, which fuses an HSP90 inhibitor with an AURKA inhibitor, as a cancer treatment approach. The proposed research aims to evaluate the...
- The University of California, San Diego (UCSD) was awarded a $2,984,495 Project Grant from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to develop and clinically validate a comprehensive liquid biopsy platform for advanced renal cell carcinoma (RCC) patients. The key objectives are to: 1) validate early on-treatment circulating tumor cell (CTC) dynamics as prognostic biomarkers, 2) validate early on-treatment CTC dynamics as predictive biomarkers for...